SBI-477

• Description :

  SBI-477 is a chemical probe that stimulates insulin signaling by deactivating the transcription factor MondoA. SBI-477 can lead to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain-containing 4 (ARRDC4) . SBI-477 coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes[1].

• UNSPSC :

  12352005

• Target :

  Arrestin; Fluorescent Dye; Insulin Receptor; LXR

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Metabolic Enzyme/Protease; Others; Protein Tyrosine Kinase/RTK; Vitamin D Related/Nuclear Receptor

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/sbi-477.html

• Concentration :

  10mM

• Purity :

  98.0

• Solubility :

  DMSO : 65 mg/mL (ultrasonic)

• Smiles :

  O=C(NC1=NC(C2=CC=C(OC)C=C2)=CS1)C3=CC=C(OCC(N4CCOCC4)=O)C(OC)=C3

• Molecular Formula :

  C24H25N3O6S

• Molecular Weight :

  483.54

• References & Citations :

  [1]Ahn B, et al. MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J Clin Invest. 2016 Sep 1;126 (9) :3567-79.|[2]Nakayama, Y., et al., (2024) . Systemic Deletion of ARRDC4 Improves Cardiac Reserve and Exercise Capacity in Diabetes. Circulation research, 135 (3), 416–433.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [781628-99-7]